Tempest Therapeutics
PublicTempest Therapeutics is now publicly traded
The data on this page reflects Tempest Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Private Placement
Sep 15, 2026
Total Funding Raised
$96.74M
Company Overview
Tempest Therapeutics operates in Biotech and is based in Brisbane, California. It has raised $96.74M.
Tempest Therapeutics is a clinical-stage biotechnology company that develops small molecule therapeutics and in vivo CAR-T cell therapies for oncology and autoimmune indications.
Sector
Biotech
AI Layer
Non-AI
Tempest Therapeutics Comparables
Compare Tempest Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ethonova | 73% | |
| FGH BioTech, Inc. | 55% | |
| ImCare Biotech, Inc. | 49% |
For institutional investors. Book with your work email.
Tempest Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Sep 15, 2026 | ||||
| Private Placement | Mar 20, 2026 | ||||
| Private Placement | Apr 26, 2022 | ||||
| Private Placement | Mar 18, 2013 | ||||
| Private Placement | Mar 29, 2012 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withSep 16, 2026
Tempest Therapeutics, Inc. partners with Senlang through an exclusive option deal for a CD7-targeted lentiviral in vivo CAR-T platform and a portfolio of candidates in cancer and autoimmune disease on Sep 15th '26.
For institutional investors. Book with your work email.
Tempest Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.